Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
J Urol. 2012 Nov;188(5):1706-11. doi: 10.1016/j.juro.2012.07.035. Epub 2012 Sep 19.
We compared the prognostic ability of the current American Joint Committee on Cancer (AJCC) staging system to direct measurement of the depth of tumor invasion into the muscularis propria and perivesical fat.
We identified 148 patients with pT2N0 and 206 with pT3N0 who underwent radical cystectomy between 1990 and 2003. Clinicopathological features were reviewed. A measurement in mm was recorded of the depth of tumor invasion into the muscularis propria for pT2 cases and into perivesical fat for pT3 cases. Cancer specific survival between the pT2a and pT2b, and the pT3a and pT3b patient groups was estimated using the Kaplan-Meier method and compared with the log rank test. Optimal cutoff points for invasion depth in mm were estimated using an iterative estimation process to find the minimum p value with the maximum HR.
Of 148 patients with pT2 bladder cancer, including 76 with pT2a and 72 with pT2b, and 206 with pT3 bladder cancer, including 144 with pT3a and 62 with pT3b, there was no significant difference in cancer specific survival between the substages (p = 0.94 and 0.37, respectively). However, patients with measured invasion less than 4.5 mm into perivesical fat had significantly improved cancer specific survival compared to that in patients with invasion 4.5 mm or greater (5-year cancer specific survival 53% vs 40%, p = 0.02).
We found no significant difference in cancer specific survival when pT2 and pT3 tumors were stratified by AJCC substage. However, for pT3 tumors direct measurement of the depth of tumor invasion into perivesical fat identified a significant stratification of cancer specific survival at 4.5 mm.
我们比较了当前美国癌症联合委员会(AJCC)分期系统与直接测量肿瘤侵犯至肌层固有层和膀胱周围脂肪的深度的预后能力。
我们确定了 1990 年至 2003 年间接受根治性膀胱切除术的 148 例 pT2N0 患者和 206 例 pT3N0 患者。回顾了临床病理特征。记录了 pT2 病例中肿瘤侵犯至肌层固有层的深度(mm)和 pT3 病例中侵犯至膀胱周围脂肪的深度(mm)。使用 Kaplan-Meier 方法和对数秩检验比较 pT2a 和 pT2b 以及 pT3a 和 pT3b 患者组之间的癌症特异性生存率。使用迭代估计过程估计入侵深度的最佳截断点,以找到具有最大 HR 的最小 p 值。
在 148 例 pT2 膀胱癌患者中,包括 76 例 pT2a 和 72 例 pT2b,206 例 pT3 膀胱癌患者中,包括 144 例 pT3a 和 62 例 pT3b,亚期之间的癌症特异性生存率无显著差异(p = 0.94 和 0.37,分别)。然而,侵犯至膀胱周围脂肪小于 4.5mm 的患者的癌症特异性生存率明显优于侵犯 4.5mm 或更大的患者(5 年癌症特异性生存率 53%比 40%,p = 0.02)。
当根据 AJCC 亚期对 pT2 和 pT3 肿瘤进行分层时,我们发现癌症特异性生存率没有显著差异。然而,对于 pT3 肿瘤,直接测量肿瘤侵犯至膀胱周围脂肪的深度可在 4.5mm 处显著分层癌症特异性生存率。